<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:06:05Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10627486" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10627486</identifier>
        <datestamp>2023-11-07</datestamp>
        <setSpec>kargersd</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="brief-report">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Cerebrovasc Dis</journal-id>
              <journal-id journal-id-type="iso-abbrev">Cerebrovasc Dis</journal-id>
              <journal-id journal-id-type="publisher-id">CED</journal-id>
              <journal-title-group>
                <journal-title>Cerebrovascular Diseases (Basel, Switzerland)</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1015-9770</issn>
              <issn pub-type="epub">1421-9786</issn>
              <publisher>
                <publisher-name>S. Karger AG</publisher-name>
                <publisher-loc>Allschwilerstrasse 10, P.O. Box · Postfach · Case postale, CH–4009, Basel, Switzerland · Schweiz · Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.com</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10627486</article-id>
              <article-id pub-id-type="pmcid">PMC10627486</article-id>
              <article-id pub-id-type="pmc-uid">10627486</article-id>
              <article-id pub-id-type="pmid">36599321</article-id>
              <article-id pub-id-type="pmid">36599321</article-id>
              <article-id pub-id-type="doi">10.1159/000528385</article-id>
              <article-id pub-id-type="publisher-id">ced-0052-0539</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Clinical Research in Stroke</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Effect of Magnesium on Deterioration and Symptomatic Hemorrhagic Transformation in Cerebral Ischemia: An Ancillary Analysis of the FAST-MAG Trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Fan</surname>
                    <given-names>Shawn</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>a</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jang</surname>
                    <given-names>Michael</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">
                    <sup>b</sup>
                  </xref>
                  <xref rid="aff3" ref-type="aff">
                    <sup>c</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kim-Tenser</surname>
                    <given-names>May</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">
                    <sup>b</sup>
                  </xref>
                  <xref rid="aff3" ref-type="aff">
                    <sup>c</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Shkirkova</surname>
                    <given-names>Kristina</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">
                    <sup>d</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Liebeskind</surname>
                    <given-names>David S.</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">
                    <sup>e</sup>
                  </xref>
                  <xref rid="aff6" ref-type="aff">
                    <sup>f</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Starkman</surname>
                    <given-names>Sidney</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">
                    <sup>e</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Villablanca</surname>
                    <given-names>Juan Pablo</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">
                    <sup>e</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hamilton</surname>
                    <given-names>Scott</given-names>
                  </name>
                  <xref rid="aff7" ref-type="aff">
                    <sup>g</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Naidech</surname>
                    <given-names>Andrew</given-names>
                  </name>
                  <xref rid="aff8" ref-type="aff">
                    <sup>h</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Saver</surname>
                    <given-names>Jeffrey L.</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">
                    <sup>e</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sanossian</surname>
                    <given-names>Nerses</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">
                    <sup>b</sup>
                  </xref>
                  <xref rid="aff3" ref-type="aff">
                    <sup>c</sup>
                  </xref>
                  <xref rid="cor1" ref-type="corresp">*</xref>
                </contrib>
              </contrib-group>
              <aff id="aff1"><sup>a</sup>Duke-NUS Medical School, Singapore, Singapore</aff>
              <aff id="aff2"><sup>b</sup>Roxanna Todd Hodges Stroke Program, University of Southern California Keck School of Medicine, Los Angeles, California, USA</aff>
              <aff id="aff3"><sup>c</sup>Department of Neurology, University of Southern California Keck School of Medicine, Los Angeles, California, USA</aff>
              <aff id="aff4"><sup>d</sup>Zilkha Neurogenetic Institute, University of Southern California Keck School of Medicine, Los Angeles, California, USA</aff>
              <aff id="aff5"><sup>e</sup>Department of Neuroradiology, University of California Los Angeles Comprehensive Stroke Center, Los Angeles, California, USA</aff>
              <aff id="aff6"><sup>f</sup>Neurovascular Imaging Core, University of California Los Angeles, Los Angeles, California, USA</aff>
              <aff id="aff7"><sup>g</sup>Department of Neurology, Stanford University School of Medicine, Stanford, California, USA</aff>
              <aff id="aff8"><sup>h</sup>Department of Neurology, Northwestern University Feinberg School of Medicine, Evanston, Illinois, USA</aff>
              <author-notes>
                <corresp id="cor1">*Nerses Sanossian, <email>sanossia@yahoo.com</email></corresp>
              </author-notes>
              <pub-date pub-type="ppub">
                <month>10</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>4</day>
                <month>1</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>4</day>
                <month>1</month>
                <year>2023</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>52</volume>
              <issue>5</issue>
              <fpage>539</fpage>
              <lpage>542</lpage>
              <history>
                <date date-type="received">
                  <day>23</day>
                  <month>7</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>24</day>
                  <month>10</month>
                  <year>2022</year>
                </date>
                <date date-type="subscription-year">
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright © 2023 by The Author(s). Published by S. Karger AG, Basel</copyright-statement>
                <copyright-year>2023</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.</license-p>
                </license>
              </permissions>
              <abstract>
                <sec>
                  <title>Background</title>
                  <p>Magnesium (Mg) is a neuroprotectant in preclinical models. Lower serum Mg levels have been associated with symptomatic hemorrhagic transformation (HT) in patients with ischemic stroke. Early treatment of acute ischemic stroke with Mg may reduce rates of symptomatic HT.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p>In this post hoc study of the Field Administration of Stroke Therapy Magnesium (FAST-MAG) trial, 1,245 participants with a diagnosis of cerebral ischemia received 20 g of Mg or placebo initiated in the prehospital setting. Posttreatment serum Mg level was measured for 809 participants. Cases of clinical deterioration, defined as worsening by ≥4 points on the National Institute of Health Stroke Scale (NIHSS), were imaged and evaluated for etiology. Symptomatic HT was defined as deterioration with imaging showing new hemorrhage.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p>Clinical deterioration occurred in 187 and symptomatic HT in 46 of 1,245 cases of cerebral ischemia. Rates of deterioration and symptomatic HT were not significantly lower in those who received Mg (15.7% vs. 14.4%, <italic>p</italic> = 0.591; 2.8% vs. 4.6%, <italic>p</italic> = 0.281). In cases where serum Mg level was obtained posttreatment, lower serum Mg level (&lt;1.7 mg/dL) was associated with significantly higher rates of deterioration and symptomatic HT (27.5% vs. 15.5%, <italic>p</italic> = 0.0261; 11.6% vs. 3.65%, <italic>p</italic> = 0.00819).</p>
                </sec>
                <sec>
                  <title>Conclusions</title>
                  <p>Treatment with Mg did not significantly reduce rates of clinical deterioration or symptomatic HT. Future analysis should address whether treatment with Mg could have influenced the subgroup with low serum Mg at baseline.</p>
                </sec>
              </abstract>
              <kwd-group>
                <title>Keywords</title>
                <kwd>Magnesium</kwd>
                <kwd>Cerebral ischemia</kwd>
                <kwd>Hemorrhagic transformation</kwd>
              </kwd-group>
              <funding-group>
                <funding-statement>The FAST-MAG trial is funded as a collaborative U01 trial by the NIH-NINDS. The performance centers include 40 emergency medical services provider agencies, 315 rescue ambulances, and 60 receiving hospitals in Los Angeles and Orange Counties. The Clinical Coordinating Center and the Core Imaging Laboratory are at the University of California, Los Angeles, the Statistical Management Center is at Mt. Tam Data Analysis with an affiliation with Stanford University, and the Data Management Center is at InClin, Inc. Drug kits are specially prepared for the study by McGuff Pharmacy, a certified research pharmacy with extensive experience in preparation of agents for IND clinical trials.</funding-statement>
              </funding-group>
              <counts>
                <table-count count="2"/>
                <ref-count count="7"/>
                <page-count count="4"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="sec1_2">
              <title>Introduction</title>
              <p>Magnesium (Mg) has been shown to be neuroprotective for acute ischemic stroke within 2 h of symptom onset in preclinical models [<xref rid="B1" ref-type="bibr">1</xref>]. Furthermore, lower serum Mg levels have been associated with higher rates of symptomatic hemorrhagic transformation (HT) [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>]. Thus, intravenous Mg sulfate could be an attractive pharmacologic treatment for the prevention of symptomatic HT because it is well tolerated and inexpensive.</p>
              <p>The NIH-funded Field Administration of Stroke Therapy Magnesium (FAST-MAG) phase 3 clinical trial randomized subjects to treatment with high dose of Mg or matched placebo with treatment infusion in standard paramedic ambulances in prehospital patients with acute stroke symptoms [<xref rid="B4" ref-type="bibr">4</xref>]. We aimed to determine if treatment with intravenous Mg reduced rates of clinical deterioration and symptomatic HT.</p>
            </sec>
            <sec sec-type="methods" id="sec1_3">
              <title>Methods</title>
              <p>Details of the multi-center FAST-MAG trial have been previously described [<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>]. Patients 40–95 years of age were eligible for inclusion if they had a suspected stroke and if treatment could be initiated within 2 h of symptom onset. The active Mg dose regimen was designed to rapidly double the normal serum Mg level and maintain that higher concentration for the first 24 h. Study protocol did not prespecify serum Mg evaluation; however, a subgroup of participants did have their posttreatment Mg levels measured.</p>
              <p>Upon hospital arrival, all patients underwent acute brain imaging and neurologic status evaluation by the National Institute of Health Stroke Scale (NIHSS), which was followed up on days 1, 2, 4, and 90. Deterioration is defined as ≥4 point increase on the NIHSS between the time of arrival and the day 4 follow-up visit. Follow-up imaging was collected on all cases of clinical deterioration. Symptomatic HT is defined as deterioration accompanied with imaging showing new hemorrhage and was centrally adjudicated by study neuroradiologist (JPV).</p>
              <p>We compared the rates of deterioration and symptomatic HT between acute ischemic stroke patients who received Mg versus placebo treatments. In addition, for the subgroup of participants who had posttreatment serum Mg measurements, we compared the rates of deterioration and symptomatic HT between participants with high/normal and low serum Mg level defined as ≤1.7 mg/dL [<xref rid="B7" ref-type="bibr">7</xref>]. Differences in the rates of deterioration and symptomatic HT were primarily assessed using the Cochran-Mantel-Haenszel test with adjustment for age (&lt;70 years vs. ≥70 years), baseline severity of stroke (Los Angeles Motor Scale [LAMS] score &lt;4 vs. ≥4), and prior history of diabetes and hypertension. For the comparison of treatment group characteristics, the independent <italic>t</italic> test was used for continuous variables that were normally distributed and the Mann-Whitney U test for those that were not, and the χ<sup>2</sup> test was used for categorical variables. The criterion for statistical significance was set at an alpha level of 0.05 throughout the analysis.</p>
            </sec>
            <sec sec-type="results" id="sec1_4">
              <title>Results</title>
              <p>A total of 1,245 cases of cerebral ischemia were evaluated by paramedics a median of 24 min (interquartile range: 14–43 min) and had study drug initiated 44 min (interquartile range: 34–59 min) after symptom onset. There were 46 cases of symptomatic HT. Patients with symptomatic HT had a higher incidence of diabetes (<italic>p</italic> &lt; 0.001) and scored higher on prehospital LAMS (<italic>p</italic> &lt; 0.001) and NIHSS (<italic>p</italic> &lt; 0.001) upon arrival.</p>
              <p>Table <xref rid="T1" ref-type="table">1</xref> compares the characteristics of the Mg and placebo treatment groups. There was no significant difference in the overall rate of clinical deterioration between treatment groups (<italic>p</italic> = 0.591). Symptomatic HT was the leading cause of deterioration in both groups. The rate of symptomatic HT was numerically lower in those who received Mg treatments, but this was not statistically significant (<italic>p</italic> = 0.281).</p>
              <p>809 out of 1,245 cases in this study had posttreatment serum Mg measurements within 24 h of infusion (406 in Mg group, 403 in placebo group). 69 out of 809 cases had low posttreatment Mg level (5 in Mg group, 64 in placebo group). Table <xref rid="T2" ref-type="table">2</xref> compares the characteristics of participants with posttreatment serum Mg level below and above 1.7 mg/dL. Low posttreatment serum Mg level was associated with significantly higher rates of in-hospital deterioration (<italic>p</italic> = 0.0261) and symptomatic HT (<italic>p</italic> = 0.00819). 11.6% of participants with low posttreatment serum Mg level experienced symptomatic HT, as compared to 3.65% of participants with normal or elevated posttreatment serum Mg level.</p>
            </sec>
            <sec sec-type="discussion" id="sec1_5">
              <title>Discussion</title>
              <p>We found that ultra-early treatment with high-dose Mg was not associated with significantly reduced rates of clinical deterioration or symptomatic HT. Previous observational studies have documented an association of higher serum Mg with reduced rates of symptomatic HT in general, post-thrombolysis, and improved clinical outcomes [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>]. We conducted an analysis of the subgroup of study participants with post-infusion Mg levels and found that low serum Mg levels were associated with deterioration and symptomatic HT.</p>
              <p>In the FAST-MAG study population, low serum Mg was associated with a 3-fold increase in rates of symptomatic HT, consistent with previous observational studies [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>]. Numerically, there were fewer cases of symptomatic HT in the Mg group compared to placebo. The most likely explanation for these findings is that only the subgroup of individuals with low serum Mg at baseline has the potential to receive a protective benefit from Mg infusion. Rates of symptomatic HT and incidence of low serum Mg were low in general in the studied population, prohibiting this analysis from describing any significant association. Future analysis should address whether treatment with Mg could influence participants with low pretreatment serum Mg levels.</p>
              <p>Limitations of our analysis include the lack of systematic follow-up imaging in those who did not experience clinical deterioration, preventing us from evaluating the effect of Mg on nonsymptomatic HT. The studied population may not be reflective of the general stroke population.</p>
              <p>In summary, treatment with high-dose Mg did not lead reduced rates of symptomatic HT. We did confirm the association of low serum Mg with symptomatic HT in our population, consistent with prior studies predominantly in the Chinese population [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>].</p>
            </sec>
            <sec id="sec1_6">
              <title>Statement of Ethics</title>
              <p>The study (ClinicalTrials.gov Identifier: NCT00059332) was approved by the Institutional Review Board (IRB) at the leading institution (University of California, Los Angeles) (IRB#11-000067; recent approval date: August 25, 2022). Explicit informed consent was obtained via cellphone conversation between on-scene patients or legally authorized representatives and off-scene enrolling physician-investigators, or under exception from informed consent regulations. The methodology and primary results of the FAST-MAG study have been previously published [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>].</p>
            </sec>
            <sec sec-type="COI-statement" id="sec1_7">
              <title>Conflict of Interest Statement</title>
              <p>The authors report no conflicts of interest.</p>
            </sec>
            <sec id="sec1_8">
              <title>Funding Sources</title>
              <p>The FAST-MAG trial is funded as a collaborative U01 trial by the NIH-NINDS. The performance centers include 40 emergency medical services provider agencies, 315 rescue ambulances, and 60 receiving hospitals in Los Angeles and Orange Counties. The Clinical Coordinating Center and the Core Imaging Laboratory are at the University of California, Los Angeles, the Statistical Management Center is at Mt. Tam Data Analysis with an affiliation with Stanford University, and the Data Management Center is at InClin, Inc. Drug kits are specially prepared for the study by McGuff Pharmacy, a certified research pharmacy with extensive experience in preparation of agents for IND clinical trials.</p>
            </sec>
            <sec id="sec1_9">
              <title>Author Contributions</title>
              <p>Shawn Fan, Dr. Michael Jang, and Dr. Nerses Sanossian conceived and designed the study, did the data analysis, interpreted the data, and wrote the manuscript. Dr. May Kim-Tenser, Kristina Shkirkova, Dr. David S. Liebeskind, Dr. Sidney Starkman, Dr. Juan Pablo Villablanca, Dr. Scott Hamilton, Dr. Andrew Naidech, and Dr. Jeffrey L. Saver reviewed and edited the manuscript. Each author has approved the submitted version and has agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated and resolved, and the resolution documented in the literature.</p>
            </sec>
            <sec sec-type="data-availability" id="sec1_10">
              <title>Data Availability Statement</title>
              <p>The main FAST-MAG trial database and materials have been made publicly available at the NIH-NINDS Archived Clinical Research Datasets and can be accessed at <ext-link xlink:href="https://www.ninds.nih.gov/Current-Research/Research-Funded-NINDS/Clinical-Research/Archived-Clinical-Research-Datasets" ext-link-type="uri">https://www.ninds.nih.gov/Current-Research/Research-Funded-NINDS/Clinical-Research/Archived-Clinical-Research-Datasets</ext-link>.</p>
            </sec>
          </body>
          <back>
            <ref-list>
              <title>References</title>
              <ref id="B1">
                <label>1</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Muir</surname>
                      <given-names>KW</given-names>
                    </name>
                  </person-group>
                  <article-title>Magnesium for neuroprotection in ischaemic stroke: rationale for use and evidence of effectiveness</article-title>
                  <source>CNS Drugs</source>
                  <year>2001</year>
                  <volume>15</volume>
                  <issue>(12)</issue>
                  <fpage>921</fpage>
                  <lpage>930</lpage>
                  <pub-id pub-id-type="pmid">11735612</pub-id>
                </element-citation>
              </ref>
              <ref id="B2">
                <label>2</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cheng</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Huang</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Muse</surname>
                      <given-names>FM</given-names>
                    </name>
                    <name>
                      <surname>Xia</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Zhan</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Lin</surname>
                      <given-names>X</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Low serum magnesium levels are associated with hemorrhagic transformation after thrombolysis in acute ischemic stroke</article-title>
                  <source>Front Neurol</source>
                  <year>2020</year>
                  <volume>11</volume>
                  <fpage>962</fpage>
                  <pub-id pub-id-type="pmid">32982953</pub-id>
                </element-citation>
              </ref>
              <ref id="B3">
                <label>3</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tan</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Yuan</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Wei</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Xu</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Serum magnesium but not calcium was associated with hemorrhagic transformation in stroke overall and stroke subtypes: a case-control study in China</article-title>
                  <source>Neurol Sci</source>
                  <year>2018</year>
                  <month>Aug</month>
                  <volume>39</volume>
                  <issue>(8)</issue>
                  <fpage>1437</fpage>
                  <lpage>1443</lpage>
                  <pub-id pub-id-type="pmid">29804167</pub-id>
                </element-citation>
              </ref>
              <ref id="B4">
                <label>4</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Saver</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Starkman</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Eckstein</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Stratton</surname>
                      <given-names>SJ</given-names>
                    </name>
                    <name>
                      <surname>Pratt</surname>
                      <given-names>FD</given-names>
                    </name>
                    <name>
                      <surname>Hamilton</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Prehospital use of magnesium sulfate as neuroprotection in acute stroke</article-title>
                  <source>N Engl J Med</source>
                  <year>2015</year>
                  <month>Feb 5</month>
                  <volume>372</volume>
                  <issue>(6)</issue>
                  <fpage>528</fpage>
                  <lpage>536</lpage>
                  <pub-id pub-id-type="pmid">25651247</pub-id>
                </element-citation>
              </ref>
              <ref id="B5">
                <label>5</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Saver</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Starkman</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Eckstein</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Stratton</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Pratt</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Hamilton</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Methodology of the Field Administration of Stroke Therapy–Magnesium (FAST-MAG) phase 3 trial: Part 1–rationale and general methods</article-title>
                  <source>Int J Stroke</source>
                  <year>2014</year>
                  <month>Feb</month>
                  <volume>9</volume>
                  <issue>(2)</issue>
                  <fpage>215</fpage>
                  <lpage>219</lpage>
                  <pub-id pub-id-type="pmid">24444116</pub-id>
                </element-citation>
              </ref>
              <ref id="B6">
                <label>6</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Saver</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Starkman</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Eckstein</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Stratton</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Pratt</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Hamilton</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Methodology of the Field Administration of Stroke Therapy–Magnesium (FAST-MAG) phase 3 trial: Part 2–prehospital study methods</article-title>
                  <source>Int J Stroke</source>
                  <year>2014</year>
                  <month>Feb</month>
                  <volume>9</volume>
                  <issue>(2)</issue>
                  <fpage>220</fpage>
                  <lpage>225</lpage>
                  <pub-id pub-id-type="pmid">24444117</pub-id>
                </element-citation>
              </ref>
              <ref id="B7">
                <label>7</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Costello</surname>
                      <given-names>RB</given-names>
                    </name>
                    <name>
                      <surname>Elin</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <name>
                      <surname>Rosanoff</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Wallace</surname>
                      <given-names>TC</given-names>
                    </name>
                    <name>
                      <surname>Guerrero-Romero</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Hruby</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Perspective: the case for an evidence-based reference interval for serum magnesium: the time has come</article-title>
                  <source>Adv Nutr</source>
                  <year>2016</year>
                  <month>Nov 10</month>
                  <volume>7</volume>
                  <issue>(6)</issue>
                  <fpage>977</fpage>
                  <lpage>993</lpage>
                  <pub-id pub-id-type="pmid">28140318</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
          <floats-group>
            <table-wrap position="float" id="T1">
              <label>Table 1</label>
              <caption>
                <p>Comparison of rates of clinical deterioration and symptomatic HT in Mg and placebo groups</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr valign="top">
                    <th rowspan="1" colspan="1"/>
                    <th align="left" rowspan="1" colspan="1">Mg (<italic>n</italic> = 613)</th>
                    <th align="left" rowspan="1" colspan="1">Placebo (<italic>n</italic> = 632)</th>
                    <th align="left" rowspan="1" colspan="1"><italic>p</italic> value</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">In-hospital deterioration, %</td>
                    <td align="left" rowspan="1" colspan="1">15.7</td>
                    <td align="left" rowspan="1" colspan="1">14.4</td>
                    <td align="left" rowspan="1" colspan="1">0.591</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Symptomatic HT, %</td>
                    <td align="left" rowspan="1" colspan="1">2.8</td>
                    <td align="left" rowspan="1" colspan="1">4.6</td>
                    <td align="left" rowspan="1" colspan="1">0.281</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Thrombolysis, %</td>
                    <td align="left" rowspan="1" colspan="1">38.4</td>
                    <td align="left" rowspan="1" colspan="1">33.6</td>
                    <td align="left" rowspan="1" colspan="1">0.750</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Prehospital LAMS</td>
                    <td align="left" rowspan="1" colspan="1">3.6 (1.3)</td>
                    <td align="left" rowspan="1" colspan="1">3.6 (1.3)</td>
                    <td align="left" rowspan="1" colspan="1">0.880</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">NIHSS at arrival</td>
                    <td align="left" rowspan="1" colspan="1">9.5 (8.5)</td>
                    <td align="left" rowspan="1" colspan="1">9.1 (8.2)</td>
                    <td align="left" rowspan="1" colspan="1">0.402</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">NIHSS 24 h</td>
                    <td align="left" rowspan="1" colspan="1">7.8 (9.5)</td>
                    <td align="left" rowspan="1" colspan="1">7.9 (9.4)</td>
                    <td align="left" rowspan="1" colspan="1">0.854</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Premorbid mRS</td>
                    <td align="left" rowspan="1" colspan="1">0.31 (0.85)</td>
                    <td align="left" rowspan="1" colspan="1">0.31 (0.85)</td>
                    <td align="left" rowspan="1" colspan="1">0.942</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">3-month mRS</td>
                    <td align="left" rowspan="1" colspan="1">3.43 (1.38)</td>
                    <td align="left" rowspan="1" colspan="1">3.67 (1.47)</td>
                    <td align="left" rowspan="1" colspan="1">0.410</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>LAMS, Los Angeles Motor Scale; mRS, modified ranking scale; NIHSS, National Institute of Health Stroke Scale. Parentheses denote standard deviation.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <table-wrap position="float" id="T2">
              <label>Table 2</label>
              <caption>
                <p>Comparison of rates of clinical deterioration and symptomatic HT in participants with posttreatment serum Mg less and greater than 1.7 mg/dL</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr valign="top">
                    <th rowspan="1" colspan="1"/>
                    <th align="left" rowspan="1" colspan="1">Mg &lt;1.7 mg/dL (<italic>n</italic> = 69)</th>
                    <th align="left" rowspan="1" colspan="1">Mg &gt;1.7 mg/dL (<italic>n</italic> = 740)</th>
                    <th align="left" rowspan="1" colspan="1"><italic>p</italic> value</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Mg group, <italic>n</italic></td>
                    <td align="left" rowspan="1" colspan="1">5</td>
                    <td align="left" rowspan="1" colspan="1">401</td>
                    <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Placebo group, <italic>n</italic></td>
                    <td align="left" rowspan="1" colspan="1">64</td>
                    <td align="left" rowspan="1" colspan="1">339</td>
                    <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Age, years</td>
                    <td align="left" rowspan="1" colspan="1">71.1 (13.5)</td>
                    <td align="left" rowspan="1" colspan="1">71.4 (13.0)</td>
                    <td align="left" rowspan="1" colspan="1">0.836</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Female gender, %</td>
                    <td align="left" rowspan="1" colspan="1">49.2</td>
                    <td align="left" rowspan="1" colspan="1">44.7</td>
                    <td align="left" rowspan="1" colspan="1">0.536</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Race, %</td>
                    <td rowspan="1" colspan="1"/>
                    <td rowspan="1" colspan="1"/>
                    <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1"> White</td>
                    <td align="left" rowspan="1" colspan="1">68.1</td>
                    <td align="left" rowspan="1" colspan="1">76.2</td>
                    <td align="left" rowspan="1" colspan="1">0.461</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1"> Black</td>
                    <td align="left" rowspan="1" colspan="1">18.8</td>
                    <td align="left" rowspan="1" colspan="1">14.3</td>
                    <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1"> Asian</td>
                    <td align="left" rowspan="1" colspan="1">11.6</td>
                    <td align="left" rowspan="1" colspan="1">8.65</td>
                    <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1"> Other</td>
                    <td align="left" rowspan="1" colspan="1">1.50</td>
                    <td align="left" rowspan="1" colspan="1">0.850</td>
                    <td rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Hispanic ethnicity, %</td>
                    <td align="left" rowspan="1" colspan="1">18.8</td>
                    <td align="left" rowspan="1" colspan="1">20.8</td>
                    <td align="left" rowspan="1" colspan="1">0.756</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Hypertension, %</td>
                    <td align="left" rowspan="1" colspan="1">82.6</td>
                    <td align="left" rowspan="1" colspan="1">78.2</td>
                    <td align="left" rowspan="1" colspan="1">0.454</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Systolic/diastolic blood pressure, mm Hg</td>
                    <td align="left" rowspan="1" colspan="1">161 (28.0)/91.0 (21.5)</td>
                    <td align="left" rowspan="1" colspan="1">156 (26.5)/87.3 (17.1)</td>
                    <td align="left" rowspan="1" colspan="1">0.123/0.181</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Diabetes, %</td>
                    <td align="left" rowspan="1" colspan="1">42.0</td>
                    <td align="left" rowspan="1" colspan="1">21.8</td>
                    <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Tobacco, %</td>
                    <td align="left" rowspan="1" colspan="1">15.9</td>
                    <td align="left" rowspan="1" colspan="1">17.3</td>
                    <td align="left" rowspan="1" colspan="1">0.873</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Previous stroke, %</td>
                    <td align="left" rowspan="1" colspan="1">2.90</td>
                    <td align="left" rowspan="1" colspan="1">8.92</td>
                    <td align="left" rowspan="1" colspan="1">0.0995</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Prehospital LAMS</td>
                    <td align="left" rowspan="1" colspan="1">3.93 (1.25)</td>
                    <td align="left" rowspan="1" colspan="1">3.71 (1.31)</td>
                    <td align="left" rowspan="1" colspan="1">0.180</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">NIHSS at arrival</td>
                    <td align="left" rowspan="1" colspan="1">13.5 (8.89)</td>
                    <td align="left" rowspan="1" colspan="1">9.49 (7.85)</td>
                    <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">NIHSS 24 h</td>
                    <td align="left" rowspan="1" colspan="1">10.8 (9.96)</td>
                    <td align="left" rowspan="1" colspan="1">6.99 (8.00)</td>
                    <td align="left" rowspan="1" colspan="1">0.005</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Premorbid mRS</td>
                    <td align="left" rowspan="1" colspan="1">0.246 (0.755)</td>
                    <td align="left" rowspan="1" colspan="1">0.292 (0.828)</td>
                    <td align="left" rowspan="1" colspan="1">0.0636</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">3-month mRS</td>
                    <td align="left" rowspan="1" colspan="1">3.07 (2.14)</td>
                    <td align="left" rowspan="1" colspan="1">2.43 (2.08)</td>
                    <td align="left" rowspan="1" colspan="1">0.0198</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">In-hospital deterioration, %</td>
                    <td align="left" rowspan="1" colspan="1">27.5</td>
                    <td align="left" rowspan="1" colspan="1">15.5</td>
                    <td align="left" rowspan="1" colspan="1">0.0261</td>
                  </tr>
                  <tr>
                    <td align="left" rowspan="1" colspan="1">Symptomatic HT, %</td>
                    <td align="left" rowspan="1" colspan="1">11.6</td>
                    <td align="left" rowspan="1" colspan="1">3.65</td>
                    <td align="left" rowspan="1" colspan="1">0.00819</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>LAMS, Los Angeles Motor Scale; mRS, modified ranking scale; NIHSS, National Institute of Health Stroke Scale. Parentheses denote standard deviation.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </floats-group>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
